Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2000
06/29/2000WO2000037677A1 Cancer related to human chromosome 16q tumor suppressor gene
06/29/2000WO2000037643A2 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
06/29/2000WO2000037640A2 Compositions and methods for the treatment of tumor
06/29/2000WO2000037639A2 Lymphocytic membrane proteins
06/29/2000WO2000037638A2 Methods and compositions for inhibiting neoplastic cell growth
06/29/2000WO2000037613A2 Human akt-3
06/29/2000WO2000037504A2 Human monoclonal antibodies to ctla-4
06/29/2000WO2000037502A2 Vascular endothelial cell growth factor antagonists and uses thereof
06/29/2000WO2000037499A1 Topoisomerase ii inhibitor
06/29/2000WO2000037489A2 Fragment of the gylcoprotein cd55/daf for producing highly effective anti-tumour medicaments and method for using the same
06/29/2000WO2000037487A1 αvβ6 INTEGRIN INHIBITORS
06/29/2000WO2000037473A1 Epothilone derivatives and their use as antitumor agents
06/29/2000WO2000037459A1 Tricyclic farnesyl protein transferase inhibitors
06/29/2000WO2000037458A1 Farnesyl protein transferase inhibitors
06/29/2000WO2000037455A1 Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
06/29/2000WO2000037450A1 NEW β-AMIDE AND β-SULFONAMIDE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS
06/29/2000WO2000037447A1 9-aminoacridine derivatives and process for the preparation thereof
06/29/2000WO2000037436A1 Sulfonamide hydroxamates
06/29/2000WO2000037422A2 Ion channel modulating agents
06/29/2000WO2000037421A1 Nephronin: a series of compounds for treatment of infectious diseases and cancer
06/29/2000WO2000037141A1 Combination chemotherapy
06/29/2000WO2000037112A1 Pharmaceutical compositions comprising immortalised endothelial cells
06/29/2000WO2000037107A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
06/29/2000WO2000037094A2 Therapeutic applications of flint polypeptides
06/29/2000WO2000037076A1 Combinations of farnesyl transferase inhibitors and irinotecan or camptothecin for treating cancer
06/29/2000WO2000037067A2 Sensitizing agents for the treatment of skin lesions
06/29/2000WO2000037065A2 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
06/29/2000WO2000037050A1 Water-insoluble drug delivery system
06/29/2000WO2000037027A1 Oil-in-water emulsion comprising a micronised biologically active agent and an appropriate emulsifier system
06/29/2000WO2000037025A2 Antibodies to truncated vegf-d and uses thereof
06/29/2000WO2000036919A1 Bone sialoprotein based toxic gene therapy for the treatment of calcified tumors and tissues
06/29/2000WO2000036918A1 Methods and compositions for treatment of cell proliferative disorders
06/29/2000WO2000012726A3 Rationally designed heparinases derived from heparinase i and ii
06/29/2000WO2000012683A3 Stem cells bearing an fgf receptor on the cell surface
06/29/2000WO2000012542A3 Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties
06/29/2000WO2000012506A3 Collections of compounds
06/29/2000WO2000012113A3 Method of modulating memory effector t-cells using a cd2-binding agent, and compositions
06/29/2000WO2000010547A3 New use of taxoid derivatives
06/29/2000WO2000006605A3 Heterominibodies
06/29/2000WO2000000610A3 Human signal peptide-containing proteins
06/29/2000WO2000000594A3 Human transferases
06/29/2000WO1999064065A3 Tumour therapy and imaging
06/29/2000WO1999063974A3 Selective estrogen receptor modulator in combination with denydroepiandrosterone (dhea) or analogues
06/29/2000WO1999055854A3 Insulin-like growth factor ii antisense oligonucleotide sequences and methods of using same to modulate cell growth
06/29/2000WO1999055386A3 Stimulus sensitive gel with radioisotope and methods of making
06/29/2000WO1998020909A3 Ex-corpore method for treating human blood cells
06/29/2000DE19954305A1 Peptide des AT¶1¶-Rezeptors und ihre Verwendung, insbesondere für die Diagnostider Präeklampsie Peptides of AT¶1¶ receptor and their use, in particular for pre-eclampsia Diagnostider
06/29/2000DE19909771A1 Substanz zur Gewinnung hochwirksamer Tumorarzneien sowie Verfahren Substance for the production of highly effective tumor drugs and methods
06/29/2000DE19860719A1 Neue Testosteronderivate und ihre Verwendung zur Langzeittherapie von Androgen-abhängigen Erkrankungen New testosterone derivatives and their use for long-term therapy of androgen-dependent diseases
06/29/2000DE19860371A1 Kosmetische oder medizinische Zubereitung für die topische Anwendung Cosmetic or medical composition for topical application
06/29/2000CA2450402A1 Methods and compositions for inhibiting cancer cell growth comprising pro224
06/29/2000CA2358508A1 Therapeutic applications of flint polypeptides
06/29/2000CA2357413A1 Sensitizing agents for the treatment of skin lesions
06/29/2000CA2356987A1 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
06/29/2000CA2356624A1 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
06/29/2000CA2356426A1 Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia
06/29/2000CA2356366A1 Oil-in-water emulsion comprising a micronised biologically active agent and an appropriate emulsifier system
06/29/2000CA2356215A1 Human monoclonal antibodies to ctla-4
06/29/2000CA2356174A1 Kidney disease detection and treatment
06/29/2000CA2355902A1 Sulfonamide hydroxamates
06/29/2000CA2355896A1 Antibodies to truncated vegf-d and uses thereof
06/29/2000CA2355879A1 Pharmaceutical compositions comprising immortalised endothelial cells
06/29/2000CA2355874A1 .alpha.v.beta.6 integrin inhibitors
06/29/2000CA2355840A1 Nephronin: a series of compounds for treatment of infectious diseases and cancer
06/29/2000CA2355251A1 New .beta.-amide and .beta.-sulfonamide carboxylic acid derivatives, their preparation and their use as endothelin receptor antagonists
06/29/2000CA2355228A1 Bone sialoprotein based toxic gene therapy for the treatment of calcified tumors and tissues
06/29/2000CA2355074A1 Lymphocytic membrane proteins
06/29/2000CA2354779A1 Tricyclic farnesyl protein transferase inhibitors
06/29/2000CA2353799A1 Methods and compositions for inhibiting neoplastic cell growth
06/29/2000CA2353775A1 Compositions and methods for the treatment of tumor
06/29/2000CA2353635A1 Anilide derivative, production and use thereof
06/29/2000CA2352326A1 Combination chemotherapy
06/29/2000CA2333626A1 Method for prevention and treatment of cancer and other cell proliferative diseases with ultrasonics
06/29/2000CA2321143A1 9-aminoacridine derivatives and process for the preparation thereof
06/28/2000EP1013764A1 Immunomodulators
06/28/2000EP1013761A2 Humanized chimeric antibody directed against ganglioside GD3
06/28/2000EP1013661A1 Novel bicyclonucleoside and oligonucleotide analogues
06/28/2000EP1013660A1 2-fluorofucosyl-n-aroylglucosamine derivatives, intermediates therefor, and processes for producing these
06/28/2000EP1013287A2 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
06/28/2000EP1013285A2 Urokinase-type plasminogen activator receptor
06/28/2000EP1013281A1 hCG therapy for the treatment of breast cancer
06/28/2000EP1012331A1 Compositions and methods for the delivery of oligonucleotides via the alimentary canal
06/28/2000EP1012320A2 Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses
06/28/2000EP1012305A1 Component of bromelain
06/28/2000EP1012304A1 Component of bromelain
06/28/2000EP1012302A1 Human nucleotide pyrophosphohydrolase
06/28/2000EP1012288A1 Novel human cystatin-like protein
06/28/2000EP1012283A1 Mage-3 peptides presented by hla class ii molecules
06/28/2000EP1012282A1 Cysteine rich receptors-train
06/28/2000EP1012281A2 Human leukocyte calcium activated potassium channel polypeptide
06/28/2000EP1012273A2 Secreted proteins and polynucleotides encoding them
06/28/2000EP1012272A1 Human apoptosis-associated protein; encoding dna is similar to p53 response mouse gene ei124
06/28/2000EP1012270A2 Kay - a novel immune system protein
06/28/2000EP1012267A2 An antisense oligonucleotide preparation method
06/28/2000EP1012266A1 Galectin 8, 9, 10 and 10sv
06/28/2000EP1012261A1 Secreted proteins and polynucleotides encoding them
06/28/2000EP1012259A2 Tumor targeted vector
06/28/2000EP1012247A1 Short peptides which selectively modulate intracellular signalling
06/28/2000EP1012240A2 Cancer immunotherapy with semi-allogeneic cells
06/28/2000EP1012232A1 Genetically modified tumor-targeted bacteria with reduced virulence
1 ... 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 ... 2211